William B. Walkup & Associates Inc. Makes New $107,000 Investment in The Chemours Company (NYSE:CC)

William B. Walkup & Associates Inc. bought a new position in The Chemours Company (NYSE:CC) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 4,739 shares of the specialty chemicals company’s stock, valued at approximately $107,000.

Several other hedge funds and other institutional investors also recently modified their holdings of CC. Marshall Wace LLP grew its stake in Chemours by 23.8% in the 2nd quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company’s stock valued at $158,213,000 after buying an additional 1,347,710 shares in the last quarter. Khrom Capital Management LLC grew its position in shares of Chemours by 54.6% in the second quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company’s stock valued at $78,016,000 after purchasing an additional 1,220,967 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its position in shares of Chemours by 6.8% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 2,824,301 shares of the specialty chemicals company’s stock valued at $63,744,000 after purchasing an additional 178,625 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Chemours by 26.7% during the 2nd quarter. American Century Companies Inc. now owns 1,811,957 shares of the specialty chemicals company’s stock valued at $40,896,000 after purchasing an additional 382,100 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Chemours by 1.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,606,453 shares of the specialty chemicals company’s stock worth $36,258,000 after purchasing an additional 22,209 shares in the last quarter. Institutional investors own 76.26% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on CC. JPMorgan Chase & Co. cut their price objective on shares of Chemours from $25.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, August 6th. Mizuho assumed coverage on shares of Chemours in a report on Friday, June 7th. They issued a “neutral” rating and a $25.00 price target for the company. BMO Capital Markets decreased their price target on shares of Chemours from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. The Goldman Sachs Group dropped their price objective on Chemours from $29.00 to $23.00 and set a “neutral” rating for the company in a research note on Tuesday, September 3rd. Finally, Barclays decreased their target price on Chemours from $22.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Wednesday, September 25th. Six analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $26.63.

Chemours Price Performance

Shares of NYSE:CC opened at $20.72 on Monday. The Chemours Company has a 1-year low of $15.10 and a 1-year high of $32.70. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.89 and a quick ratio of 1.01. The business has a fifty day moving average price of $19.57 and a 200-day moving average price of $23.65. The company has a market capitalization of $3.09 billion, a PE ratio of -9.55 and a beta of 1.74.

Chemours (NYSE:CC) last issued its quarterly earnings results on Thursday, August 1st. The specialty chemicals company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.19). Chemours had a net margin of 2.16% and a return on equity of 33.21%. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the previous year, the business earned $1.10 earnings per share. Chemours’s revenue was down 6.4% compared to the same quarter last year. As a group, equities analysts expect that The Chemours Company will post 1.33 EPS for the current fiscal year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Thursday, August 15th were issued a $0.25 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $1.00 annualized dividend and a yield of 4.83%. Chemours’s payout ratio is -46.08%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.